Abstracting and indexing services form the backbone of modern scientific communication. When a journal is accepted into the Science Citation Index Expanded, it means that its published articles are systematically cataloged, metadata is extracted and standardized, and the content becomes discoverable through the Web of Science platform maintained by Clarivate. This process is far more than a bureaucratic formality. Inclusion in a major citation index determines whether researchers around the world can efficiently locate, retrieve, and cite a journal’s content. For pharmaceutical scientists, whose work often spans chemistry, pharmacology, formulation science, and clinical research, discoverability through trusted indexes is essential to ensuring that findings reach the practitioners and regulators who can act upon them.

The Science Citation Index Expanded, originally established as part of the Science Citation Index created by Eugene Garfield in the 1960s, has long served as one of the most selective and influential databases in academic publishing. Journals are admitted only after a rigorous evaluation process that examines editorial rigor, peer-review integrity, regularity of publication, international editorial diversity, and the citation behavior of the published literature. The fact that the Journal of Pharmaceutical Investigation entered SciSearch coverage in 2021 means that its articles published from that year onward are now tracked within the citation network that underpins modern bibliometrics, including the annual Journal Impact Factor calculations.

The Impact Factor itself remains the most widely recognized, and most widely debated, quantitative measure of a journal’s influence. Calculated each year by Clarivate, the metric reflects the average number of citations received in a given year by articles published in the journal during the two preceding years. An Impact Factor of 5.5 for 2022 indicates that, on average, articles published in the journal in 2020 and 2021 were cited 5.5 times in 2022 across the indexed literature. In the highly competitive Pharmacology and Pharmacy category, where hundreds of journals compete for the attention of a global research community, this average places the Journal of Pharmaceutical Investigation in the top tier of its discipline.

The quartile designation adds important context to the raw number. Ranking 48th among 278 journals in Pharmacology and Pharmacy corresponds to the Q1 band, the highest quartile of the category. Quartile rankings are derived by ordering all journals in a category by their Impact Factor and dividing the list into four equal groups. Q1 status is frequently used by research institutions, funding agencies, and university committees as a shorthand marker of journal prestige, influencing decisions about where researchers submit their work, how publications are weighted in hiring and promotion evaluations, and which journals libraries prioritize in their subscriptions. For authors weighing where to publish their pharmaceutical research, a Q1 designation with a 5.5 Impact Factor signals a venue with demonstrated reach and citation performance.

Pharmacology and pharmacy is one of the most densely populated categories in the Web of Science, reflecting the breadth of research that falls under its umbrella. The category encompasses basic pharmacological research into drug receptors and signaling pathways, medicinal chemistry and drug design, pharmacokinetics and drug metabolism, formulation and delivery technologies, clinical pharmacology, and pharmacy practice research. Journals in this space range from highly specialized outlets focused on narrow subfields to broad-spectrum publications that cover the full arc from molecule to medicine. Within this crowded landscape, achieving a position in the upper fifth of the category requires consistent publication of work that other researchers find useful enough to cite, year after year.

The Journal of Pharmaceutical Investigation has built its reputation on content that spans pharmaceutical technology, drug delivery systems, biopharmaceutics, and the clinical investigation of medicines. Its scope reflects the realities of contemporary drug development, where advances increasingly emerge at the boundaries between disciplines. Novel formulations such as lipid nanoparticles, long-acting injectables, and targeted delivery platforms demand expertise that bridges physical pharmacy, materials science, and regulatory science. Similarly, the evaluation of biosimilars, generics, and novel therapeutic modalities requires integration of analytical chemistry, pharmacokinetic modeling, and clinical trial methodology. A journal that serves as a conduit for this interdisciplinary work occupies a valuable position in the scientific ecosystem, and its citation performance suggests that the community recognizes that value.

Indexing in SciSearch also carries practical consequences for the researchers who publish in the journal. Articles included in the Science Citation Index Expanded are assigned digital object identifiers and standardized metadata that feed into institutional research information systems, national assessment exercises, and funder reporting requirements. In many countries, publication in indexed journals is a formal criterion for doctoral degree completion, grant eligibility, and academic advancement. For authors based in the Asia-Pacific region and beyond, where the Journal of Pharmaceutical Investigation has historically maintained strong connections through its publisher and editorial network, the journal’s expanded indexing profile enhances the portability and recognition of their published work across international evaluation systems.

The timing of the journal’s entry into the citation index is also noteworthy. Coverage beginning in 2021 means the journal’s recent publication record has been captured during a period of extraordinary activity in pharmaceutical research. The global pandemic accelerated investment in vaccine technology, antiviral therapeutics, and manufacturing science, while parallel advances in biologics, cell and gene therapies, and digital health technologies reshaped the drug development pipeline. Citation activity across pharmacology surged during this period, and journals positioned at the interface of pharmaceutical formulation and clinical investigation benefited from heightened attention to their subject matter. The 5.5 Impact Factor for 2022 reflects not only the journal’s editorial strategy but also the intensity of scientific exchange in its field during the measurement window.

Looking ahead, the combination of SciSearch indexing and Q1 standing positions the Journal of Pharmaceutical Investigation to attract submissions from a broader international author base and to deepen its role in shaping discourse on pharmaceutical innovation. Metrics are never a complete measure of a journal’s contribution, and the scholarly community continues to debate the appropriate weight given to Impact Factors in research assessment. Nevertheless, the journal’s current profile, indexed from 2021 with an Impact Factor of 5.5 and a Q1 ranking of 48 out of 278 in Pharmacology and Pharmacy, provides an objective snapshot of its standing. For a publication devoted to the investigation of medicines from laboratory bench to patient bedside, the numbers confirm what its readers and contributors have long understood: rigorous pharmaceutical science, when curated and disseminated effectively, earns its place at the center of the global research conversation.

Subject of Research: Indexing and citation metrics of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, Science Citation Index Expanded, SciSearch, Impact Factor, Q1 journal, Pharmacology and Pharmacy, abstracting and indexing, Clarivate, Web of Science, pharmaceutical sciences, journal metrics, drug development

Abstracting and indexing is the process by which a bibliographic database systematically catalogs a journal’s articles, capturing standardized metadata such as titles, authors, affiliations, abstracts, keywords and references, and making that metadata searchable across a global platform. The practical consequence for researchers is discoverability. An article that appears only on an individual journal website exists in a kind of bibliographic isolation, reachable mainly by readers who already know the journal. Once a journal is indexed in the Science Citation Index Expanded, its content becomes discoverable through Web of Science search tools, its citation links become traceable through the database’s cited-reference searching, and its cumulative performance becomes visible to the librarians, funders and evaluation committees who rely on these databases when they assess journals and institutions. In an era when most literature discovery begins with a database query rather than a browse of a journal’s table of contents, indexing status is a structural determinant of a paper’s audience.

The Science Citation Index Expanded is the multidisciplinary extension of the original Science Citation Index, the citation database created by Eugene Garfield in the 1960s and now maintained as part of the Web of Science Core Collection. The index covers thousands of journals across the natural sciences, applied sciences and medicine, and its selection process is deliberately selective. Editors evaluating a journal for inclusion consider a range of quality signals: the rigor and consistency of peer review, the international diversity of the editorial board and authorship, the regularity of publication, the ethical publishing standards in place, and the citation behavior of the journal’s published content. Journals are re-evaluated continuously, and inclusion is not permanent, which means that a journal’s presence in the index is itself an ongoing signal that its editorial standards continue to meet the database’s criteria.

The impact factor reported alongside the indexing record is the metric most closely watched by authors deciding where to submit their work. Calculated annually by Clarivate from the citation data in the Web of Science, the two-year impact factor for a given year is the ratio of citations received in that year to the number of substantive items, typically articles and reviews, published in the journal during the two preceding years. A 2022 impact factor of 5.5 therefore reflects citations accumulated in 2022 by papers published in 2020 and 2021, divided by the count of those papers. For a journal that entered the index in 2021, this figure arrives early in its indexed life, since new journals typically need a settling period before their citation patterns stabilize. The value of 5.5 indicates that, on average, each citable item published in the journal during the measurement window drew more than five citations in the following year, a level of citation intensity that corresponds to a strong, internationally visible research venue in the pharmaceutical field.

Quartile placement translates that raw number into context. Journals in a Web of Science category are ranked by impact factor and divided into four groups, with the first quartile, Q1, containing the top 25 percent. The Journal of Pharmaceutical Investigation’s position at 48 out of 278 journals in Pharmacology and Pharmacy places it firmly within that top band, ahead of roughly four-fifths of the journals in its category. The rank matters because impact factors are meaningful only in comparison. A value of 5.5 might be modest in a field with extremely high citation rates and exceptional in a field where citation density is low; the quartile ranking situates the journal relative to the actual distribution of its peers in pharmacology and pharmacy. Authors evaluating potential outlets, and readers skimming reference lists for authoritative sources, use these rankings as a fast heuristic for gauging where a journal stands within its discipline.

The downstream effects of this status are practical for the research community. Authors gain a publication venue whose indexed metrics can be cited in grant applications, promotion dossiers and funder reports, where journal quality is often assessed through Web of Science-based indicators. Institutions benefit because their researchers’ publications contribute to institutional citation profiles and to the global university rankings that draw heavily on Web of Science data. Readers benefit from the cited-reference network that the index builds, allowing them to trace the lineage of a finding backward through earlier work and forward through later citations. Librarians use the indexing record and the impact factor when making subscription decisions, which in turn supports the journal’s financial sustainability. In this way, a single indexing milestone ripples outward through nearly every stakeholder in the scientific communication system.

The pharmaceutical sciences present a particularly demanding environment for journal metrics. The field spans drug discovery, formulation science, pharmacokinetics, drug delivery systems, clinical pharmacology and regulatory science, and its publication landscape is crowded with long-established titles backed by major societies and commercial publishers. Citation behavior in the field is shaped by translational urgency: work on delivery platforms, biologics and therapeutic development often draws attention from both basic researchers and clinical communities, which can drive citation counts upward for journals positioned at those intersections. A journal focused on pharmaceutical investigation sits naturally in that translational zone, and the first-quartile ranking suggests that its published research is being picked up across both the pharmaceutical technology and the pharmacology communities that make up its readership.

At the same time, the announcement is a fitting occasion to recall the limits of the metrics involved. The research community has increasingly emphasized responsible use of quantitative indicators. The San Francisco Declaration on Research Assessment, signed by thousands of journals, funders and institutions, urges that impact factors not be used as a surrogate for the quality of individual papers or the merit of individual researchers, since citation counts are influenced by article type, review articles inflate averages, and two-year windows capture only a slice of a paper’s scholarly lifetime. Altitude within a quartile shifts year to year as citation patterns fluctuate, and a journal’s impact factor is a property of the journal, not a guarantee about any single article it publishes. The appropriate reading of the 2022 record is therefore as a signal of the journal’s overall standing and editorial health, not as a per-article quality certificate.

For the broader community of pharmaceutical researchers, the development adds one more indexed, first-quartile outlet to a field where the demand for visible, credible publication venues remains intense. Inclusion in the Science Citation Index Expanded from 2021 onward means that the journal’s recent volumes are being woven into the global citation fabric that underlies literature search, systematic review, bibliometric analysis and research evaluation. Its 2022 impact factor of 5.5 and its Q1 position at 48 of 278 journals in Pharmacology and Pharmacy provide a quantified snapshot of that integration. Whether the journal sustains and improves those numbers will depend on the same fundamentals that determine any journal’s trajectory: the quality and relevance of the research it attracts, the rigor of its peer review, and its continued adherence to the editorial standards that earned it entry into one of scholarly publishing’s most closely watched databases.

Subject of Research: Indexing of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded and its 2022 impact factor of 5.5 in pharmacology and pharmacy.

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: abstracting and indexing, Science Citation Index Expanded, impact factor, Journal of Pharmaceutical Investigation, pharmacology, pharmacy, Web of Science, quartile ranking, scholarly publishing, pharmaceutical sciences, journal metrics, research visibility